Intellia Therapeutics (NTLA) is a biotherapeutics company. On June 11, the stock fell ~9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.
The above chart compares analysts’ recommendations for Intellia stock over the last 12 months.
Intellia and the news
Intellia Therapeutics develops revolutionary genome-editing therapies using CRISPR-CAS9 Gene Therapy. CRISPR-CAS9 is a DNA cutting system used to modify DNA and cure diseases.
In response to the news that CRISPR-CAS9 might cause cancer, Intellia Therapeutics announced that no signs of toxicity or cells transforming to tumors have been observed in its in-vivo or ex-vivo programs.
Currently, the company has four in-vivo programs in the pipeline. Three of them are for genetic diseases, and one is for infectious diseases. Only one program—transthyretin amyloidosis—is in late-stage preclinical development.
There are five ex-vivo programs in the pipeline. Three of them are for immune-oncology, one is for hematology, and one is for autoimmune diseases. Among these, only one program—sickle cell disease—is in late-stage preclinical development.
Intellia stock has risen ~94.9% over the last 12 months. It has risen ~27.8% year-to-date. Analysts estimate that the stock will rise ~98.5% over the next 12 months. They have given it a 12-month target price of $48.75, which compares to $24.56 on June 11.
On June 12, there are seven analysts tracking Intellia stock. Three of them are recommending a “strong buy,” three are recommending a “buy,” and one is recommending a “hold.” None of the analysts are recommending a “sell.”
The consensus rating for Intellia is 1.7, which represents a “buy” for long-term investors as well as momentum investors.